Alnylam Pharmaceuticals (ALNY) Liabilities and Shareholders Equity (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Liabilities and Shareholders Equity of $5.1 billion for Q1 2026, up 3.29% on a QoQ basis from $5.0 billion in Q4 2025, and up 21.73% year-over-year from $4.2 billion in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $5.1 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 21.73% year-over-year to $5.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.5 billion (up 17.07% YoY) and the FY2025 annual result came in at $5.0 billion, up 17.13% from the prior year.
- Liabilities and Shareholders Equity was $5.1 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $5.0 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $5.1 billion in Q1 2026 and bottomed at $3.3 billion in Q2 2022.
- A 5-year average of $4.0 billion and a median of $3.8 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 5.1% — and 2026, when it increased 21.73%.
- Alnylam Pharmaceuticals' Liabilities and Shareholders Equity stood at $3.5 billion in 2022, then increased by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then climbed by 17.13% to $5.0 billion in 2025, then increased by 3.29% to $5.1 billion in 2026.
- Business Quant data shows ALNY's Liabilities and Shareholders Equity at $5.1 billion in Q1 2026, $5.0 billion in Q4 2025, and $4.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.25 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.13 Bn |
| Dec 31, 2025 | 4.97 Bn |
| Sep 30, 2025 | 4.85 Bn |
| Jun 30, 2025 | 4.57 Bn |
| Mar 31, 2025 | 4.21 Bn |
| Dec 31, 2024 | 4.24 Bn |
| Sep 30, 2024 | 4.21 Bn |
| Jun 30, 2024 | 4.01 Bn |
| Mar 31, 2024 | 3.82 Bn |
| Dec 31, 2023 | 3.83 Bn |
| Sep 30, 2023 | 3.84 Bn |
| Jun 30, 2023 | 3.40 Bn |
| Mar 31, 2023 | 3.39 Bn |
| Dec 31, 2022 | 3.55 Bn |
| Sep 30, 2022 | 3.54 Bn |
| Jun 30, 2022 | 3.33 Bn |
| Mar 31, 2022 | 3.43 Bn |
| Dec 31, 2021 | 3.64 Bn |
| Sep 30, 2021 | 3.47 Bn |
| Jun 30, 2021 | 3.51 Bn |